Related Experiment Video
Updated: May 28, 2026
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients
Mauricio Venegas1, Rodrigo A Villanueva, Katherine González
1Centro de Estudios Avanzados de las Hepatitis Virales, Sección de Gastroenterología, Departamento de Medicina, Hospital Clínico Universidad de Chile, 8340457 Santiago, Chile. mvenegas@redclinicauchile.cl
Aim:
To analyze the association of three IL28B single nucleotide polymorphisms with response to therapy in Chilean patients infected with hepatitis C virus (HCV).
Methods:
We studied two groups of patients with chronic HCV infection (genotype 1), under standard combined treatment with pegylated interferon plus ribavirin. One group consisted of 50 patients with sustained virological response, whereas the second group consisted of 49 null responders. In order to analyze the IL28B single nucleotide polymorphisms rs12979860, rs12980275 and rs8099917, samples were used for polymerase chain reaction amplification, and the genotyping was performed by restriction fragment length polymorphism.
Results:
The IL28B rs12979860 CC, rs12980275 AA and rs8099917 TT genotypes were much more frequently found in patients with sustained virological response compared to null responders (38%, 44% and 50% vs 2%, 8.2% and 8.2%, respectively). These differences were highly significant in all three cases (P < 0.0001).
Conclusion:
The three IL28B polymorphisms studied are strongly associated with sustained virological response to therapy in Chilean patients with chronic HCV (genotype 1).
